Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

PrEP drugs: is the NHS letting down patients at risk of HIV?

The efficacy of HIV-prevention drug PrEP is long-established, but access to the drug in England is restricted to participants on the NHS Impact Trial. At least 15 men who were waiting for trial places have acquired the lifelong disease – so how is limiting trial places for a crucial drug already proven to work justified?


Go Top